



Agenus R&D update & Second Quarter Earnings Report

July 29, 2020

Video Meeting on Thursday August 6, 2020 from 8:30 - 10:30 am

LEXINGTON, Mass., July 29, 2020 [/PRNewswire/](#) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapy, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it will provide an update on programs and plans and release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020. Agenus executives and thought leaders will host a video conference call and webcast at 8:30 a.m. ET.



Topics to be discussed:

- **Registration plans and strategy for balstilimab +/- zalifrelimab**
- **Agenus & Betta Pharmaceuticals partnership progress for China**
- **Clinical status/next steps for AGEN1181 (NextGen CTLA-4) +/- balstilimab (anti-PD-1)**
- **Allogeneic iNKT cells** potential breakthrough for COVID-19 and cancer based on efficacy and cost
- **Cell therapy and antibody combinations** preclinically show curative potential
- **AGEN1223 & AGEN2373** clinical update and plans for bali +/- zali combos
- **Myeloid immune response modifiers (TIGIT bispecific & other novel targets)**

Live Call: Dial 1-844-492-3727 (U.S.) or 1-412-317-5118 (International)

Webcast: The call will be accessible from the Company's website at <http://investor.agenusbio.com/presentation-webcasts> or via <https://www.webcaster4.com/Webcast/Page/1556/35715>. A replay will be available approximately two hours after the call and will remain available until November 7, 2020.

About Agenus

Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our Twitter handle @agenus_bio.

Contact

Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com

SOURCE Agenus Inc.